Weekly channel feed

Ver­tex's $4.9B bet; Lay­offs at No­var­tis, Genen­tech, Sanofi; Star founders un­veil new star­tups; and more

6 days ago

US-Chi­na ten­sions per­sist; Gen­mab's $1.8B ADC bet; New obe­si­ty start­up in town; ALS drug with­draw­al; and more

Last week

Re­turn of the megarounds; Nvidia’s AI pitch to biotech; Bay­er’s shake­up reach­es the top; As­traZeneca buys in­to ra­dio­phar­ma; and more

4 weeks ago

WuXi fall­out re­ver­ber­ates; Phar­ma's top R&D spenders; Lil­ly teams up with Ama­zon; His­toric NASH ap­proval; and more

Last month

Amy­lyx’s ALS dis­ap­point­ment; Lil­ly's Alzheimer's de­lay; Bay­er stays put; No­vo Nordisk's GLP-1 streak; and more

Last month

Eli Lil­ly’s Alzheimer’s trek; No­vo Nordisk puts down US roots; Sarep­ta and gene ther­a­py ac­cel­er­at­ed ap­provals; and more

Last month

Ab­b­Vie’s next CEO; $100B club re­fresh; Top 100 VCs, 2023; More hope for CAR-T in au­toim­mune; and more

Last month

Gilead­'s $4.3B liv­er bet; WuXi un­der fire; Ex­sci­en­tia CEO’s ouster; Late Fri­day cell ther­a­py ap­proval; and more

2 months ago

No­vo Hold­ings’ $16.5B bid for Catal­ent; No­var­tis’ $2.9B bolt-on; End­points Slack in­ter­view with John Evans; and more

2 months ago

End of Aduhelm’s road; Janet Wood­cock ex­it in­ter­view; Stu­art Schreiber's $500M ex­per­i­ment; Ver­tex's pain break­through; and more

2 months ago

Sanofi's $1.7B rare dis­ease gam­bit; CAR-T boxed warn­ing saga; New biotechs on Nas­daq; A sell­er's mar­ket for M&A?; and more

2 months ago

Bay­er rolls out big changes; 2024's biotech IPO queue; Dupix­en­t's 'next big thing'; 23and­Me's strug­gle with dual iden­ti­ty; and more

3 months ago

Four buy­outs (and one ru­mor that didn’t ma­te­ri­al­ize); Iso­mor­phic Lab­s' first phar­ma deals; A CAR-T IPO; #JPM24 high­lights; and more

3 months ago

Roche leads pre-JPM deal spree; Roger Perl­mut­ter’s new phar­ma force; In­side Sage’s big tri­umph and fail­ure; Late Fri­day IPO fil­ings; All new drugs in 2023; and more

3 months ago

Pfiz­er's tur­moil; FTC's new tar­get; Aviv Regev Q&A; As­traZeneca's vac­cine gam­bit; Best of #ASH23; and more

4 months ago

Ab­b­Vie’s $8.7B neu­ro gam­bit; Land­mark sick­le cell ap­provals; Roche buys a GLP-1 com­pa­ny; End­points 100 biotech sur­vey; and more

4 months ago

FDA’s CAR-T safe­ty probe; Ab­b­Vie’s $10B ADC wa­ger; Pfiz­er’s GLP-1 set­back; Ace­lyrin’s CRO dra­ma; and more

4 months ago

Mer­ck­'s neu­ro-in­spired buy­out; Bay­er's bad week; One launch, one shut­down for Flag­ship; and more

4 months ago

Land­mark CRISPR ap­proval; Why don't in­vestors like Verve’s base edit­ing da­ta?; Janet Wood­cock to re­tire; Late Fri­day IPO fil­ing; and more

5 months ago

As­traZeneca leans in­to GLP-1; Cuts loom­ing at Bay­er; Eli Lil­ly’s obe­si­ty ap­proval; End­points Slack in­ter­view with Matt Gline; and more

5 months ago

Lat­est news on BioN­Tech's Fri­day buy­out; Un­pack­ing Sarep­ta’s Duchenne da­ta; Pfiz­er’s post-Covid plans; Eli Lil­ly, As­traZeneca's gene edit­ing deals; and more

5 months ago

Roche's $7.1B bet on Roivant drug; AD­Cs and oth­er #ES­MO23 dis­patch; High­lights from Alzheimer's con­fab; Q3 phar­ma dra­ma; and more

5 months ago

Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in clin­ic; and more

6 months ago

BMS buys Mi­rati for $4.8B; Pfiz­er to slash cost; Q&A with Ver­tex CSO; Al­ny­lam's On­pat­tro set­back; and more

6 months ago
1234 Next page Last page
A service from the Financial Times